Eli Lilly nears deal to buy psychedelic drugmaker Atai Beckley, Bloomberg reports

• The deal could be announced within days, indicating negotiations are in final stages
• AtaiBeckley specializes in psychedelic drug development, representing a new therapeutic area for Eli Lilly
• Neither Eli Lilly nor AtaiBeckley has provided official comment on the acquisition talks

Summary: Eli Lilly Nears Acquisition of Psychedelic Drugmaker Atai Beckley

Key Development:

Pharmaceutical giant Eli Lilly is in advanced discussions to acquire AtaiBeckley, a psychedelic drugmaker, with a deal potentially being announced as early as this week, according to Bloomberg News citing sources familiar with the matter.

Companies Involved:

• Eli Lilly: Major pharmaceutical company expanding its therapeutic portfolio
• AtaiBeckley: Psychedelic drug development company

Sector Implications:

This potential acquisition signals growing mainstream pharmaceutical interest in the psychedelic medicine sector, which has gained increased attention for treating mental health conditions including depression, PTSD, and anxiety disorders. Eli Lilly's move reflects the industry's broader shift toward innovative mental health treatments beyond traditional pharmaceuticals.

Deal Status:

The transaction is still in negotiation phase, with both companies declining to comment outside regular business hours. No financial terms or deal value have been disclosed at this stage.

Market Context:

This development comes as major pharmaceutical companies increasingly seek to diversify their pipelines and capitalize on emerging therapeutic areas. The psychedelic medicine space has attracted significant investment and regulatory attention in recent years, with several compounds progressing through clinical trials.

Timeline:

An announcement could come within days (as of July 15 reporting), though the deal has not been finalized. The rapid timeline suggests negotiations are at an advanced stage.

This acquisition, if completed, would strengthen Eli Lilly's position in the mental health treatment market and provide access to psychedelic drug development expertise and pipeline assets.